JMP Securities Lowers Kura Oncology Price Target to $24, Maintains Market Outperform Rating

JMP Securities analyst Reni Benjamin has lowered the price target for Kura Oncology (KURA) from $28 to $24, maintaining a "Market Outperform" rating. This decrease represents a 14.29% decrease in the price target. The analyst's adjustment is based on the company's clinical-stage biopharmaceutical pipeline targeting cancer signaling pathways.

JMP Securities has revised its price target for Kura Oncology (NASDAQ: KURA) from $28.00 to $24.00, while maintaining a "Market Outperform" rating. The adjustment, announced on July 2, 2025, represents a 14.29% decrease in the price target. The analyst's decision is based on an updated analysis of the company's clinical-stage biopharmaceutical pipeline, which targets cancer signaling pathways.

The current stock price of Kura Oncology is $5.54, down over 70% from its peak in the past year and nearing its 52-week low of $5.41 [1]. Despite the stock's decline, JMP Securities remains optimistic about Kura's long-term prospects. The firm cited its updated discounted EPS and revenue multiple analysis as the basis for the lower target but emphasized that Kura shares still represent an attractive investment opportunity.

One of the key factors influencing JMP Securities' decision is the company's lead drug candidate, zifto, which is on track for potential approval in the fourth quarter of 2025. The drug candidate received FDA Priority Review with a PDUFA date of November 30, 2025 [2]. Additionally, Kura Oncology's strong cash position of $630.7 million is expected to fully fund its planned front-line trials scheduled to begin in the second half of 2025.

In other recent news, Kura Oncology reported its Q2 2025 earnings, revealing a substantial shortfall in revenue expectations. The company posted actual revenue of $15.3 million, significantly below the forecasted $39.1 million, marking a 60.88% deficit. The earnings per share (EPS) were also lower than anticipated, with a reported loss of $0.75 compared to the expected loss of $0.41 [1]. These figures highlight the challenges Kura Oncology is currently facing in meeting financial projections.

While the company's stock experienced a minor decline in after-hours trading following the earnings report, the focus remains on the earnings and revenue figures. Investors are likely to keep a close watch on any further developments from the company. These recent developments underscore the importance of monitoring Kura Oncology’s financial performance closely.

References:
[1] https://www.investing.com/news/analyst-ratings/kura-oncology-stock-price-target-lowered-to-24-at-citizens-jmp-93CH-4181987
[2] https://ir.kuraoncology.com/news-releases/news-release-details/kura-oncology-reports-second-quarter-2025-financial-results